Invokana linked to flesh-eating genital infections. According to the latest FDA warnings Invokana, Jardiance, Farxiga and similar diabetes drugs increase the risk of serious genital infections.
The FDA issued a warning earlier this week, warning that the drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors increase the risk of serious genital infections.
According to the FDA, “In the five years from March 2013 to May 2018, we identified 12 cases of Fournier’s gangrene in patients taking an SGLT2 inhibitor. This number includes only reports submitted to FDA and found in the medical literature, so there may be additional cases about which we are unaware.”
New FDA Infection Warning Labels
The FDA is requiring new label infection warnings be added to all drugs that belong to the class, including Invokana, Invokamet, Invokamet XR, Farxiga, Xigduo XR, Qtern, Jardiance, Glyxambi, Synjardy, Synjardy XR, Steglatro, Segluromet, and Steglujan.
The FDA notes that the infections developed within several months of beginning treatment with one of the drugs and all 12 patients underwent hospitalization and surgery. At least one patient died, while others suffered disfiguring surgeries and other serious complications.
Diabetic Patients Shocked over Invokana Amputation side effects
Johnson & Johnson and it’s Janssen subsidiary are under intense scrutiny over claims that the companies failed to adequately research the potential side effects of Invokana.
Diabetic folks are frightened and angry over the increased risk of serious and in some cases catastrophic side effects of Invokana.
Diabetic patients are shocked and fearful because Invokana has been linked to an increased risk of diabetic ketoacidosis, kidney failure, and leg amputations.
What is Invokana?
Invokana (canagliflozin) was approved for sale in March 2013, as the first member of a new class of diabetes drugs, known as sodium-glucose cotransporter 2 (SGLT2) inhibitors.
Similar SGLT2 drugs include Invokamet, Jardiance, Farxiga, Xigduo, and Invokana has the largest market share.
Invokana Injury lawsuits over 1,000
The Invokana side effect injury cases are concentrated in the U.S. District Court for the District of New Jersey, and more than 1,000 have been filed for centralization and coordination for pretrial proceedings, as part of a federal multidistrict litigation (MDL).
The Invokana side effect cases involve three different injury categories, kidney failure, diabetic ketoacidosis, and allegations that Invokana increases the risk of amputations.
FDA Warnings over Invokana Side Effects
Since Invokana’s release, there have been many reports of catastrophic health complications from patients taking the type 2 diabetic medication. The FDA has ordered many warning label updates over the past several years.
In December 2015, the FDA ordered Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, finding that the drug increases the risk of this dangerous medical condition.
In June 2016, the FDA ordered new label warnings about Invokana and kidney risks, finding that the drug increases the risk of acute kidney failure.
In May 2017, the FDA ordered new label warnings about Invokana and the increased risk of leg and foot amputations.
If you or someone you know developed Invokana Ketoacidosis, leg, foot, toes amputations or kidney failure by taking Invokana for the treatment of their type 2 diabetes, please call us for further information at 214-390-3189. Dr. Shezad Malik Law Firm based in Dallas, Texas is investigating Invokana Wrongful death, Invokana Ketoacidosis, leg amputations, and kidney failure cases nationwide from folks taking Invokana for the treatment of their type 2 diabetes.